Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 327Neoplasm Metastasis 40Neoplasms 25Advanced Breast Cancer 19Ovarian Neoplasms 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Multiple Endocrine Neoplasia Type 1 5Carcinoma, Ovarian Epithelial 5Breast Diseases 5Neoplasms by Site 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Breast Neoplasm Female 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Fulvestrant × Clear all
NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT04778982 2023-07-17

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated
4 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡